Literature DB >> 29264621

[Long-term results of adjuvant versus early salvage radiation therapy in pT3N0 prostate cancer after radical prostatectomy].

R M Hermann1, H Christiansen2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29264621     DOI： 10.1007/s00066-017-1242-6

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  9 in total

Review 1.  Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling.

Authors:  Nitin Ohri; Adam P Dicker; Edouard J Trabulsi; Timothy N Showalter
Journal:  Eur J Cancer       Date:  2011-09-22       Impact factor: 9.162

2.  Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial.

Authors:  Thomas Wiegel; Detlef Bartkowiak; Dirk Bottke; Claudia Bronner; Ursula Steiner; Alessandra Siegmann; Reinhard Golz; Stephan Störkel; Normann Willich; Axel Semjonow; Michael Stöckle; Christian Rübe; Udo Rebmann; Tilman Kälble; Horst Jürgen Feldmann; Manfred Wirth; Rainer Hofmann; Rita Engenhart-Cabillic; Axel Hinke; Wolfgang Hinkelbein; Kurt Miller
Journal:  Eur Urol       Date:  2014-03-21       Impact factor: 20.096

3.  Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Bertrand Tombal; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Marc Colombel; Cees van de Beek; Paul Verhagen; Alphonsus van den Bergh; Cora Sternberg; Thomas Gasser; Geertjan van Tienhoven; Pierre Scalliet; Karin Haustermans; Laurence Collette
Journal:  Lancet       Date:  2012-10-19       Impact factor: 79.321

4.  Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.

Authors:  Lars Budäus; Jonas Schiffmann; Markus Graefen; Hartwig Huland; Pierre Tennstedt; Alessandra Siegmann; Dirk Böhmer; Volker Budach; Detlef Bartkowiak; Thomas Wiegel
Journal:  Strahlenther Onkol       Date:  2017-05-03       Impact factor: 3.621

5.  Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis.

Authors:  Alberto Briganti; Thomas Wiegel; Steven Joniau; Cesare Cozzarini; Marco Bianchi; Maxine Sun; Bertrand Tombal; Karin Haustermans; Tom Budiharto; Wolfgang Hinkelbein; Nadia Di Muzio; Pierre I Karakiewicz; Francesco Montorsi; Hein Van Poppel
Journal:  Eur Urol       Date:  2012-05-16       Impact factor: 20.096

6.  Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy.

Authors:  Jung Julie Kang; Robert E Reiter; Michael L Steinberg; Christopher R King
Journal:  J Urol       Date:  2014-11-14       Impact factor: 7.450

7.  Competing event risk stratification may improve the design and efficiency of clinical trials: secondary analysis of SWOG 8794.

Authors:  Kaveh Zakeri; Brent S Rose; Sachin Gulaya; Anthony V D'Amico; Loren K Mell
Journal:  Contemp Clin Trials       Date:  2012-10-11       Impact factor: 2.226

Review 8.  The timing of salvage radiotherapy after radical prostatectomy: a systematic review.

Authors:  Christopher R King
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-07-14       Impact factor: 7.038

9.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.

Authors:  Ian M Thompson; Catherine M Tangen; Jorge Paradelo; M Scott Lucia; Gary Miller; Dean Troyer; Edward Messing; Jeffrey Forman; Joseph Chin; Gregory Swanson; Edith Canby-Hagino; E David Crawford
Journal:  J Urol       Date:  2009-01-23       Impact factor: 7.450
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.